To investigate clinical efficacy and safety of @ certolizumab pegol ( CZP ) maintenance dosing regimens plus methotrexate ( MTX ) in active rheumatoid arthritis ( RA ) patients achieving the American College of Rheumatology @ % improvement criteria ( ACR@ ) after the CZP @ mg every @ weeks open-label run-in period .